# Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals

> **NCT03125629** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 53 (actual)

## Conditions studied

- Cancer Diagnosis
- Diagnostic Techniques and Procedures
- Diagnostic Imaging

## Interventions

- **DRUG:** F-18 FDG
- **DRUG:** Ga-68-DOTA-TATE
- **DEVICE:** Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- **DEVICE:** Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan

## Key facts

- **NCT ID:** NCT03125629
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-27
- **Primary completion:** 2016-11-30
- **Final completion:** 2020-02-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125629, "Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03125629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*